慢性肾脏病-矿物质骨紊乱治疗中降全段甲状旁腺激素药物研究进展  

Research progress of drugs to reduce whole intact parathyroid hormone in the treatment of chronic kidney disease-mineral and bone disorder

作　　者：张倩楠[1] 汪年松[2] 李军辉[1] ZHANG Qiannan;WANG Niansong;LI Junhui(Department of Nephrology,Tongji University Affiliated Putuo People's Hospital,Shanghai 200060,China;Department of Nephrology,Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University,Shanghai 200233,China)

机构地区：[1]同济大学附属普陀人民医院肾内科,上海200060 [2]上海交通大学医学院附属第六人民医院肾内科,上海200233

出　　处：《世界临床药物》2025年第1期23-28,共6页World Clinical Drug

基　　金：上海市普陀区科委课题(ptkwws202412);上海市普陀区人民医院院级课题(2022rmky12)。

摘　　要：继发性甲状旁腺功能亢进(secondary hyperparathyroidism,SHPT)是慢性肾脏病-矿物质骨紊乱(chronic kidney disease-mineral and bone disorder,CKD-MBD)的重要并发症之一,可显著增加患者骨骼畸形、心血管事件及死亡的发生风险。在目前CKD-MBD SHPT的临床治疗中,磷结合剂、拟钙剂、多核铁-氢氧化物及tenapanor等药物均展现出一定优势;新型活性维生素D类似物可有效降低全段甲状旁腺激素(intact parathyroid hormone,iPTH)水平。该文对近年来降iPTH CKD的MBD治疗药物进展作一综述,旨在为临床用药提供参考。Secondary hyperparathyroidism(SHPT)is one of the most important complications of chronic kidney disease-mineral and bone disorder(CKD-MBD),which can significantly increase the risk of bone deformities,cardiovascular events,and death.In the current treatment of CKD-MBD SHPT,phosphorus binders,calcium-like agents,polynuclear iron-hydroxide and tenapanor have shown advantages.Novel active vitamin D analogues can effectively reduce the level of intact parathyroid hormone(iPTH).This article reviewed the recent progress of IPTH-decreasing CKD-MBD drugs in order to provide reference for clinical use.

关 键 词：慢性肾脏病-矿物质骨紊乱 继发性甲状旁腺功能亢进症 全段甲状旁腺激素 

分 类 号：R692[医药卫生—泌尿科学] R589.2[医药卫生—外科学]